Cogent Biosciences (COGT) Total Non-Current Liabilities (2019 - 2026)

Cogent Biosciences (COGT) has reported Total Non-Current Liabilities for 7 consecutive years, with $295.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 355.65% year-over-year to $295.3 million; the TTM figure through Mar 2026 stood at $295.3 million (up 355.65% YoY), while the FY2025 annual figure was $301.2 million, up 320.6% from the prior year.
• Total Non-Current Liabilities slipped to $295.3 million in Q1 2026 per COGT's latest filing, from $301.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $301.2 million in Q4 2025 and bottomed at $43.4 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $145.0 million across 4 years, with a median of $117.4 million in 2025.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 192.13% — and 2026, when it surged 355.65%.
• Cogent Biosciences' Total Non-Current Liabilities stood at $43.4 million in 2022, then soared by 65.1% to $71.6 million in 2024, then soared by 320.6% to $301.2 million in 2025, then declined by 1.98% to $295.3 million in 2026.
• Business Quant data shows COGT's Total Non-Current Liabilities at $295.3 million in Q1 2026, $301.2 million in Q4 2025, and $121.1 million in Q3 2025.